Yogesh A. Karpe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yogesh A. Karpe has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Gayatri D. Kanade
Agharkar Research Institute, Nanobioscience Group, G. G. Agarkar Road, Pune 411004, India
6 shared publicationsKunal D. Pingale
Savitribai Phule Pune University, Ganeshkhind, Pune 411 007, India
6 shared publicationsPooja Salunke
Agharkar Research Institute, Nanobioscience Group, Pune, India
2 shared publicationsSurajit Patra
Nanobioscience Group, Agharkar Research Institute, Pune 411004, India
2 shared publications- Virendra Gajbhiye
Nanobioscience Group, Agharkar Research Institute, Pune 411004, India; Savitribai Phule Pune University, Pune 411007, India
2 shared publications Kalyan Banerjee
Nanobioscience Group, Agharkar Research Institute, G. G. Agarkar Road, Pune, 411004, India
1 shared publication
Latest Publications
- Open Access
- 16 July 2026
- Published by Springer Nature in Discover Viruses
- Vol. 3 (1) , 15
Impact of hepatitis E virus ORF1 mutations on virus replication and disease severity
Hepatitis E virus (HEV) Open Reading Frame 1 (ORF1) encodes a non-structural polyprotein. It has domains of methyl transferase, Y domain, fatty acid binding domain, hypervariable domain, X domain, helicase, and RNA-dependent RNA polymerase. Meta-analysis of virus-host interaction and immunological studies suggested that HEV ORF1 plays a significant role in HEV pathogenesis. Many virus-host interaction studies suggest that potential open reading frame 1 (pORF1) domains interact with host factors involved in various pathways, such as metabolism, innate immune pathways, etc. Interestingly, many in vitro studies showed that the mutations in ORF1 regions alter the virus replication efficiency in cell culture; this suggests the importance of ORF1 in virus pathogenesis. Similarly, the genome sequence analysis of HEV-infected patients reveals that specific amino acid mutations in ORF1 contribute to the disease severity. Studies have empirically proven the association of specific ORF1 mutations in fulminant hepatitis failure (FHF) patients and their effects on HEV replication efficiency using reverse genetic systems. These ORF1 amino acid mutations enhance viral fitness and likely contribute to poor clinical outcomes. Additionally, genotype-specific mutations show different pathogenic significance, contributing to differences in disease outcomes across HEV genotypes. In summary, apart from its role in virus replication, the ORF1 protein interacts with various host factors and contributes to pathogenesis. Mutations in ORF1 are one of the factors that contribute to the development of FHF in HEV-infected patients. This review summarises literature on pORF1 and its role in HEV pathogenesis.
- 16 July 2026
- Published by Springer Nature in Discover Viruses
- Vol. 3 (1) , 15
Open AccessImpact of hepatitis E virus ORF1 mutations on virus replication and disease severity
Hepatitis E virus (HEV) Open Reading Frame 1 (ORF1) encodes a non-structural polyprotein. It has domains of methyl transferase, Y domain, fatty acid binding domain, hypervariable domain, X domain, helicase, and RNA-dependent RNA polymerase. Meta-analysis of virus-host interaction and immunological studies suggested that HEV ORF1 plays a significant role in HEV pathogenesis. Many virus-host interaction studies suggest that potential open reading frame 1 (pORF1) domains interact with host factors involved in various pathways, such as metabolism, innate immune pathways, etc. Interestingly, many in vitro studies showed that the mutations in ORF1 regions alter the virus replication efficiency in cell culture; this suggests the importance of ORF1 in virus pathogenesis. Similarly, the genome sequence analysis of HEV-infected patients reveals that specific amino acid mutations in ORF1 contribute to the disease severity. Studies have empirically proven the association of specific ORF1 mutations in fulminant hepatitis failure (FHF) patients and their effects on HEV replication efficiency using reverse genetic systems. These ORF1 amino acid mutations enhance viral fitness and likely contribute to poor clinical outcomes. Additionally, genotype-specific mutations show different pathogenic significance, contributing to differences in disease outcomes across HEV genotypes. In summary, apart from its role in virus replication, the ORF1 protein interacts with various host factors and contributes to pathogenesis. Mutations in ORF1 are one of the factors that contribute to the development of FHF in HEV-infected patients. This review summarises literature on pORF1 and its role in HEV pathogenesis.
- Open Access
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens
Stimulation of adaptive immunity is a goal to defend against infectious agents. In recent years, vaccine development and improvements in their efficacy have been thoroughly investigated, and highly effective vaccines have been released to the market. The administration of vaccinations, safety, and the development of immunogenicity pose considerable challenges in this area. Investigations have been conducted on nanoparticle (NP)-based vaccines to address the issue. NPs are used in vaccine development to enhance antigen delivery, provide protection, and serve as adjuvants. The application of nanotechnology has substantially improved the delivery and effectiveness of vaccines by manipulating NP properties. Studies on NP-based immunizations have focused on viral pathogens and bacterial agents. Immunizations utilizing NPs enhance immune responses and stabilize viral antigens, facilitating the development of vaccines for hepatitis B, influenza, and HIV. Nanovaccines specifically target antigens associated with viruses, bacteria, and certain cancers. NP-based vaccines effectively stimulate and mature dendritic cells (DCs) in vitro and in vivo. Following vaccination, the NP-based vaccine resulted in increased cytokine levels and activated Th1 and Th2 cells in vivo. As a result, NP-based vaccines stimulate T-cell immune responses and adaptive immunity driven by immunoglobulin G and immunoglobulin M. This review has discussed the various NPs and antigens used in nanovaccine preparation; the role NPs play in activating adaptive immunity; and, specifically, the maturation of DCs; the activation of Th1 and Th2 cells against viruses, bacteria, and other microbial pathogens; and the safety of NPs.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Open AccessNanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens
Stimulation of adaptive immunity is a goal to defend against infectious agents. In recent years, vaccine development and improvements in their efficacy have been thoroughly investigated, and highly effective vaccines have been released to the market. The administration of vaccinations, safety, and the development of immunogenicity pose considerable challenges in this area. Investigations have been conducted on nanoparticle (NP)-based vaccines to address the issue. NPs are used in vaccine development to enhance antigen delivery, provide protection, and serve as adjuvants. The application of nanotechnology has substantially improved the delivery and effectiveness of vaccines by manipulating NP properties. Studies on NP-based immunizations have focused on viral pathogens and bacterial agents. Immunizations utilizing NPs enhance immune responses and stabilize viral antigens, facilitating the development of vaccines for hepatitis B, influenza, and HIV. Nanovaccines specifically target antigens associated with viruses, bacteria, and certain cancers. NP-based vaccines effectively stimulate and mature dendritic cells (DCs) in vitro and in vivo. Following vaccination, the NP-based vaccine resulted in increased cytokine levels and activated Th1 and Th2 cells in vivo. As a result, NP-based vaccines stimulate T-cell immune responses and adaptive immunity driven by immunoglobulin G and immunoglobulin M. This review has discussed the various NPs and antigens used in nanovaccine preparation; the role NPs play in activating adaptive immunity; and, specifically, the maturation of DCs; the activation of Th1 and Th2 cells against viruses, bacteria, and other microbial pathogens; and the safety of NPs.
- Open Access
- 20 March 2025
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 13, 1524405
Recombinant protein expression in Acanthamoeba castellanii
The ongoing quest to improve protein production efficiency, quality, and versatility fuels the exploration of novel expression systems. In this research, we explored the potential of the axenically culturable Acanthamoeba as an alternative for producing recombinant eukaryotic proteins. We constructed plasmid vectors utilizing the TBP promoter to facilitate recombinant protein expression within this protozoan system. Our primary objectives were to develop an efficient transfection method and assess the capacity of Acanthamoeba castellanii for glycoprotein expression. Our initial efforts yielded successful expression of the firefly luciferase reporter gene, allowing us to optimize the transfection protocol. Subsequently, we compared the expression of the Chikungunya virus E2 protein across three systems: E. coli, Acanthamoeba, and mammalian cells. Interestingly, the E2 protein expressed in Acanthamoeba exhibited a molecular weight higher than bacterial cells but lower than mammalian cells, suggesting the possibility of glycosylation occurring in the protozoan system. These findings collectively suggest that protozoa, like A. castellanii, represent a promising avenue for developing low-cost and efficient eukaryotic expression systems.
- 20 March 2025
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 13, 1524405
Open AccessRecombinant protein expression in Acanthamoeba castellanii
The ongoing quest to improve protein production efficiency, quality, and versatility fuels the exploration of novel expression systems. In this research, we explored the potential of the axenically culturable Acanthamoeba as an alternative for producing recombinant eukaryotic proteins. We constructed plasmid vectors utilizing the TBP promoter to facilitate recombinant protein expression within this protozoan system. Our primary objectives were to develop an efficient transfection method and assess the capacity of Acanthamoeba castellanii for glycoprotein expression. Our initial efforts yielded successful expression of the firefly luciferase reporter gene, allowing us to optimize the transfection protocol. Subsequently, we compared the expression of the Chikungunya virus E2 protein across three systems: E. coli, Acanthamoeba, and mammalian cells. Interestingly, the E2 protein expressed in Acanthamoeba exhibited a molecular weight higher than bacterial cells but lower than mammalian cells, suggesting the possibility of glycosylation occurring in the protozoan system. These findings collectively suggest that protozoa, like A. castellanii, represent a promising avenue for developing low-cost and efficient eukaryotic expression systems.
- Open Access
- 7 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1500622
Assessment of heat-killed E. coli expressing Chikungunya virus E2 protein as a candidate vaccine for dual protection against Chikungunya virus and E. coli
The Chikungunya virus (CHIKV) is a mosquito-borne virus with a long history of recurring epidemics transmitted through Aedes mosquitoes. The rapid spread of CHIKV has intensified the need for potent vaccines. Escherichia coli (E.coli), a vital part of human gut microbiota, is utilized in recombinant DNA technology for cloning. However, its high adaptability can lead to severe infections in humans. This study aimed to develop the candidate dual vaccine against CHIKV and E. coli. For this, we expressed the CHIKV E2 protein in the E. coli Rosetta Bl21 cells and the protein expression was confirmed by western blotting. The IgG immune response of the candidate vaccine was determined against CHIKV and E. coli by ELISA. Further, the potential of antibodies to neutralize CHIKV was evaluated via Tissue Culture Infectious Dose 50 (TCID50). We observed that cells expressing E2 protein with alum immunized mice serum showed a five-fold higher IgG immune response against CHIKV, compared to control cells. The CHIKV neutralization assay results showed a two-fold decrease in CHIKV TCID50 value after 12 hours and a three-fold reduction after 120 hours. Similarly, the vaccine formulation also elicited a significantly higher IgG immune response against E. coli. The results suggested that expressing CHIKV E2 protein in E. coli is a potential approach for generating an IgG immune response against CHIKV and E. coli both. This study proposes a faster, safer, and cost-effective recombinant protein-based vaccine development.
- 7 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1500622
Open AccessAssessment of heat-killed E. coli expressing Chikungunya virus E2 protein as a candidate vaccine for dual protection against Chikungunya virus and E. coli
The Chikungunya virus (CHIKV) is a mosquito-borne virus with a long history of recurring epidemics transmitted through Aedes mosquitoes. The rapid spread of CHIKV has intensified the need for potent vaccines. Escherichia coli (E.coli), a vital part of human gut microbiota, is utilized in recombinant DNA technology for cloning. However, its high adaptability can lead to severe infections in humans. This study aimed to develop the candidate dual vaccine against CHIKV and E. coli. For this, we expressed the CHIKV E2 protein in the E. coli Rosetta Bl21 cells and the protein expression was confirmed by western blotting. The IgG immune response of the candidate vaccine was determined against CHIKV and E. coli by ELISA. Further, the potential of antibodies to neutralize CHIKV was evaluated via Tissue Culture Infectious Dose 50 (TCID50). We observed that cells expressing E2 protein with alum immunized mice serum showed a five-fold higher IgG immune response against CHIKV, compared to control cells. The CHIKV neutralization assay results showed a two-fold decrease in CHIKV TCID50 value after 12 hours and a three-fold reduction after 120 hours. Similarly, the vaccine formulation also elicited a significantly higher IgG immune response against E. coli. The results suggested that expressing CHIKV E2 protein in E. coli is a potential approach for generating an IgG immune response against CHIKV and E. coli both. This study proposes a faster, safer, and cost-effective recombinant protein-based vaccine development.
- Open Access
- 3 June 2024
- Published by Frontiers Media SA in Frontiers: A Journal of Women Studies
- Vol. 4, 1386580
Role of miRNAs in the Chikungunya virus replication and pathogenesis
Chikungunya virus (CHIKV) is a vector-born alphavirus responsible for chikungunya fever with clinical manifestation of polyarthritis transmitted by Aedes aegypti and Aedes albopictus. Establishing viral pathogenesis needs host machinery modulation, and the microRNAs (miRNA) modulate host cellular machinery to establish the infection or inhibit viral replication. miRNAs are the small noncoding RNA that control the gene expression. They are essential in cell differentiation, growth, development, and apoptosis. It also affects disease progression, cancer, and viral infection. CHIKV infection causes differential expression of miRNA, and miRNA has target genes involved in different cellular functions. These target genes may be crucial in CHIKV replication and cell growth. Suppression or overexpression of these miRNAs may have been linked with CHIKV pathogenesis by regulating immune and signaling pathways. Identification of biomarkers in disease progression through the study of circulating miRNAs during CHIKV infection is an emerging field. Therefore, understanding miRNAs’ differential expression and function during CHIKV infection is essential. The detailed studies on the miRNA-mediated regulatory network will provide new ways to develop miRNA-based therapies.
- 3 June 2024
- Published by Frontiers Media SA in Frontiers: A Journal of Women Studies
- Vol. 4, 1386580
Open AccessRole of miRNAs in the Chikungunya virus replication and pathogenesis
Chikungunya virus (CHIKV) is a vector-born alphavirus responsible for chikungunya fever with clinical manifestation of polyarthritis transmitted by Aedes aegypti and Aedes albopictus. Establishing viral pathogenesis needs host machinery modulation, and the microRNAs (miRNA) modulate host cellular machinery to establish the infection or inhibit viral replication. miRNAs are the small noncoding RNA that control the gene expression. They are essential in cell differentiation, growth, development, and apoptosis. It also affects disease progression, cancer, and viral infection. CHIKV infection causes differential expression of miRNA, and miRNA has target genes involved in different cellular functions. These target genes may be crucial in CHIKV replication and cell growth. Suppression or overexpression of these miRNAs may have been linked with CHIKV pathogenesis by regulating immune and signaling pathways. Identification of biomarkers in disease progression through the study of circulating miRNAs during CHIKV infection is an emerging field. Therefore, understanding miRNAs’ differential expression and function during CHIKV infection is essential. The detailed studies on the miRNA-mediated regulatory network will provide new ways to develop miRNA-based therapies.
- Open Access
- 5 January 2024
- Published by Frontiers Media SA in Frontiers: A Journal of Women Studies
- Vol. 3, 1327745
Processing of the Hepatitis E virus ORF1 nonstructural polyprotein
Hepatitis E viruses (HEV) Open Reading Frame 1 (ORF1) encodes a non-structural polyprotein. In most positive-sense RNA viruses found in animals, this non-structural polyprotein is cleaved by viral protease or host protease. However, the mechanism behind the processing of HEV polyprotein remains one of the most controversial questions in HEV biology. The role of putative HEV protease in processing is difficult to demonstrate. Recent studies have questioned the existence of HEV protease and suggested that pORF1 lacks protease activity. Conversely, studies also suggested the role of host proteases involved in the blood coagulation cascade, like thrombin, in processing the HEV pORF1 polyprotein. In summary, recent studies support the notion that pORF1 lacks protease activity and host proteases are responsible for processing pORF1. The present review compiles a thorough overview of contentious research on HEV’s papain-like cysteine protease (PCP) and highlights recent advancements in the field. We aim to discuss the challenges and opportunities in the field to focus on further research.
- 5 January 2024
- Published by Frontiers Media SA in Frontiers: A Journal of Women Studies
- Vol. 3, 1327745
Open AccessProcessing of the Hepatitis E virus ORF1 nonstructural polyprotein
Hepatitis E viruses (HEV) Open Reading Frame 1 (ORF1) encodes a non-structural polyprotein. In most positive-sense RNA viruses found in animals, this non-structural polyprotein is cleaved by viral protease or host protease. However, the mechanism behind the processing of HEV polyprotein remains one of the most controversial questions in HEV biology. The role of putative HEV protease in processing is difficult to demonstrate. Recent studies have questioned the existence of HEV protease and suggested that pORF1 lacks protease activity. Conversely, studies also suggested the role of host proteases involved in the blood coagulation cascade, like thrombin, in processing the HEV pORF1 polyprotein. In summary, recent studies support the notion that pORF1 lacks protease activity and host proteases are responsible for processing pORF1. The present review compiles a thorough overview of contentious research on HEV’s papain-like cysteine protease (PCP) and highlights recent advancements in the field. We aim to discuss the challenges and opportunities in the field to focus on further research.
- 16 March 2023
- Published by Elsevier in Journal of Molecular Biology
- Vol. 435 (10) , 168050
Unravelling the Tripartite Interactions Among Hepatitis E Virus RNA, miR-140 and hnRNP K
- 16 March 2023
- Published by Elsevier in Journal of Molecular Biology
- Vol. 435 (10) , 168050
Unravelling the Tripartite Interactions Among Hepatitis E Virus RNA, miR-140 and hnRNP K
- Open Access
- 17 February 2022
- Published by Microbiology Society in Journal of General Virology
- Vol. 103 (2) , 001711
Corrigendum: Hepatitis E virus polymerase binds to IFIT1 to protect the viral RNA from IFIT1-mediated translation inhibition
Microbiology Society journals contain high-quality research papers and topical review articles. We are a not-for-profit publisher and we support and invest in the microbiology community, to the benefit of everyone. This supports our principal goal to develop, expand and strengthen the networks available to our members so that they can generate new knowledge about microbes and ensure that it is shared with other communities.
- 17 February 2022
- Published by Microbiology Society in Journal of General Virology
- Vol. 103 (2) , 001711
Open AccessCorrigendum: Hepatitis E virus polymerase binds to IFIT1 to protect the viral RNA from IFIT1-mediated translation inhibition
Microbiology Society journals contain high-quality research papers and topical review articles. We are a not-for-profit publisher and we support and invest in the microbiology community, to the benefit of everyone. This supports our principal goal to develop, expand and strengthen the networks available to our members so that they can generate new knowledge about microbes and ensure that it is shared with other communities.
- 1 September 2020
- Published by Elsevier in Journal of Molecular Biology
- Vol. 432 (19) , 5322-5342
Uncovering the Roles of miR-214 in Hepatitis E Virus Replication
- 1 September 2020
- Published by Elsevier in Journal of Molecular Biology
- Vol. 432 (19) , 5322-5342
Uncovering the Roles of miR-214 in Hepatitis E Virus Replication
- 1 March 2020
- Published by Elsevier in Journal of Molecular Biology
- Vol. 432 (7) , 2369-2387
Heterogeneous Nuclear Ribonucleoproteins Participate in Hepatitis E Virus Replication
- 1 March 2020
- Published by Elsevier in Journal of Molecular Biology
- Vol. 432 (7) , 2369-2387
Heterogeneous Nuclear Ribonucleoproteins Participate in Hepatitis E Virus Replication